AI English summary of an SEC filing — figures as filed

Elevance Health said operating revenue for Q1 2024 was $42.3 billion, up 0.9% from a year earlier, and diluted EPS was $9.59, up 15.5%.

8-KResults of Operations and Financial ConditionFiled Apr 18, 2024Period of report Apr 18, 2024Summary published (UTC) Oct 21, 2026

Key points

AI summary

Elevance Health said operating revenue for Q1 2024 was $42.3 billion, up 0.9% from a year earlier, and diluted EPS was $9.59, up 15.5%.
The company said it raised its full-year diluted EPS guidance to greater than $34.05 and its adjusted diluted EPS guidance to greater than $37.20. Adjusted diluted EPS for Q1 was $10.64, up 12.5%.
Elevance Health said operating cash flow for Q1 2024 was $2.0 billion, or 0.9 times net income. It repurchased 1.1 million shares for $566 million and paid $379 million in dividends.
The company said operating revenue for its Carelon segment in Q1 2024 was $12.1 billion, up $0.6 billion (5%) from a year earlier, and operating gain was $0.8 billion, up 10%.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Q1 2024 operating revenue $42.3 billion

Elevance Health said operating revenue for Q1 2024 was $42.3 billion, up 0.9% from a year earlier, and diluted EPS was $9.59, up 15.5%.

Source · Based on the filing body and exhibits

Raises full-year EPS guidance

The company said it raised its full-year diluted EPS guidance to greater than $34.05 and its adjusted diluted EPS guidance to greater than $37.20. Adjusted diluted EPS for Q1 was $10.64, up 12.5%.

Source · Based on the filing body and exhibits

Q1 2024 operating cash flow and shareholder returns

Elevance Health said operating cash flow for Q1 2024 was $2.0 billion, or 0.9 times net income. It repurchased 1.1 million shares for $566 million and paid $379 million in dividends.

Source · Based on the filing body and exhibits

Carelon segment operating revenue and operating gain

The company said operating revenue for its Carelon segment in Q1 2024 was $12.1 billion, up $0.6 billion (5%) from a year earlier, and operating gain was $0.8 billion, up 10%.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.